Mefluidide diolamine salt

415.42800

415.13887653 g/mol

367H5E6MS0

DTXSID3034298

139.63000

3.27810

0.69 g/cu cm at 25 °C

106-108 °C

574.3ºC

301.1ºC

In water, 556 mg/g at 25 °C

<1.0X10-7 mm Hg at 25 °C

100% dissociates in aqueous solution. Mefluidide pKa = 4.6 /Mefluidide/

SRP: Recycle any unused portion of the material for its approved use or return it to the manufacturer or supplier. Ultimate disposal of the chemical must consider: the material's impact on air quality; potential migration in air, soil or water; effects on animal, aquatic and plant life; and conformance with environmental and public health regulations. If it is possible or reasonable use an alternative chemical product with less inherent propensity for occupational harm/injury/toxicity or environmental contamination.

USEPA/Office of Prevention, Pesticides and Toxic Substances; Reregistration Eligibility Decision Document - Mefluidide, EPA 738-R-07-011 (September 2007). The RED summarizes the risk assessment conclusions and outlines any risk reduction measures necessary for the pesticide to continue to be registered in the USA.[Available from, as of July 9, 2018: http://www.epa.gov/pesticides/reregistration/status.htm]

Mefluidide and its DEA salt were not dermally toxic when tested in rabbits at limit doses of 1000 mg/kg/day for 21 days. Effects were limited to slight erythema at the application site at the 1000 mg/kg/day dose.

IDENTIFICATION AND USE: Mefluidide-diolamine is a plant growth regulator and pesticide. HUMAN STUDIES: There are no data available. ANIMAL STUDIES: Mefluidide-diolamine was not dermally toxic when tested in rabbits at doses of 1000 mg/kg/day for 21 days. Effects were limited to slight erythema at the application site at the 1000 mg/kg/day dose. There were no treatment-related malformations or developmental variations when tested in rats. Clinical signs of neurotoxicity (such as tremors, ataxia, atonia, decreased limb tone, salivation) were seen in several studies (14-day oral in rabbit at or above 200 mg/kg/day, demyelination study in chickens at 1000 mg/kg/day and two developmental toxicity studies in rats at 115 mg/kg/day. Edema and swelling with myelin loss in sciatic nerve was observed in a dermal toxicity study in rabbits at doses of 720 mg/kg and above. However, these effects were not seen in an additional dermal test of similar duration using a 28.8% formulation of mefluidide-diolamine. Mefluidide-diolamine was assayed for induction of reverse mutations at the histidine locus of Salmonella typhimurium tester strains TA98, TA100, TA1535, TA1537 and TA1538 and it was negative with or without metabolic activation. ECOTOXICITY STUDIES: Mefluidide-diolamine was practically non-toxic to rainbow trout (Oncorhynchus mykiss), bluegill sunfish (Lepomis macrochirus), sheepshead minnow (Cyprinodon variegatus, waterflea (Daphnia magna, and to the estuarine marine mysid (Mysidopsis bahia). It was slightly toxic to the estuarine marine eastern oyster (Crassostrea virginica). It was practically nontoxic to honeybees on an acute contact basis. In plants symptoms of toxicity included stunting, chlorosis, necrosis and distortion.

/AQUATIC SPECIES/ Mefluidide-DEA is practically non-toxic to the estuarine marine mysid (Mysidopsis bahia), with a 96-hr EC50 >94.5 mg acid equivalent (ae)/L and a NOAEC of 31.5 mg ae/L. Mean measured concentrations were 15, 26, 42, 75 and 126 mg ai/L (11.25, 19.5, 31.5, 56.2 and 94.5 mg ae/L). One mortality to estuarine marine mysid occurred at the 52.2 mg ae/L treatment level and 2 mortalities occurred in the 94.5 mg ae/L treatment level. No other mortalities or sublethal effects occurred during the test.|/AQUATIC SPECIES/ Mefluidide-DEA is practically non-toxic to the cold water species, rainbow trout (Oncorhynchus mykiss), with a non-definitive 96-hour LC50 of >68.47 mg acid equivalent (ae)/L and a NOAEC of 68.47 mg ae/L (MRID 418937-02). No mortalities or sublethal signs of toxicity in rainbow trout were observed with test material in any of the tested concentrations. The mean measured concentrations were 15.2, 12.5, 24.4, 45.2, and 91.3 mg ai/L. (11.4, 9.3, 18.3, 33.9 and 68.4 mg ae/L).|/AQUATIC SPECIES/ Mefluidide-DEA is practically non-toxic to the warm water species, bluegill sunfish (Lepomis macrochirus) with a non-definitive 96-hour LC50 of >70.80 mg acid equivalent (ae)/L and a NOAEC of 70.80 mg ae/L. No mortalities or sublethal signs of toxicity in bluegill sunfish were observed with test material in any of the tested concentrations. The mean measured concentrations were 14.6, 19.7, 32.4, 58.3 and 94.4 mg ai/L(10.9, 14.7, 24.3, 43.7 and 70.8 mg ae/L).|/AQUATIC SPECIES/ Mefluidide-DEA is practically non-toxic to sheepshead minnow (Cyprinodon variegatus), with a non-definitive 96-hour LC50 of >84.75 mg acid equivalent (ae)/L and a NOAEC of 84.75 mg ae/L. No mortalities or sublethal signs of toxicity in sheephead minnow were observed with test material in any of the tested concentrations. The mean measured concentrations were 16, 28, 34, 68, and 113 mg ai/L (12, 21, 25.5, 51 and 84.7 mg ae/L).|For more Ecotoxicity Excerpts (Complete) data for Mefluidide-diolamine (9 total), please visit the HSDB record page.

/SRP:/ Immediate first aid: Ensure that adequate decontamination has been carried out. If patient is not breathing, start artificial respiration, preferably with a demand valve resuscitator, bag-valve-mask device, or pocket mask, as trained. Perform CPR if necessary. Immediately flush contaminated eyes with gently flowing water. Do not induce vomiting. If vomiting occurs, lean patient forward or place on left side (head-down position, if possible) to maintain an open airway and prevent aspiration. Keep patient quiet and maintain normal body temperature. Obtain medical attention. /Poisons A and B/|/SRP:/ Basic treatment: Establish a patent airway (oropharyngeal or nasopharyngeal airway, if needed). Suction if necessary. Watch for signs of respiratory insufficiency and assist ventilations if needed. Administer oxygen by nonrebreather mask at 10 to 15 L/min. Monitor for pulmonary edema and treat if necessary ... . Monitor for shock and treat if necessary ... . Anticipate seizures and treat if necessary ... . For eye contamination, flush eyes immediately with water. Irrigate each eye continuously with 0.9% saline (NS) during transport ... . Do not use emetics. For ingestion, rinse mouth and administer 5 mL/kg up to 200 mL of water for dilution if the patient can swallow, has a strong gag reflex, and does not drool ... . Cover skin burns with dry sterile dressings after decontamination ... . /Poisons A and B/|/SRP:/ Advanced treatment: Consider orotracheal or nasotracheal intubation for airway control in the patient who is unconscious, has severe pulmonary edema, or is in severe respiratory distress. Positive-pressure ventilation techniques with a bag valve mask device may be beneficial. Consider drug therapy for pulmonary edema ... . Consider administering a beta agonist such as albuterol for severe bronchospasm ... . Monitor cardiac rhythm and treat arrhythmias as necessary ... . Start IV administration of D5W TKO /SRP: "To keep open", minimal flow rate/. Use 0.9% saline (NS) or lactated Ringer's (LR) if signs of hypovolemia are present. For hypotension with signs of hypovolemia, administer fluid cautiously. Watch for signs of fluid overload ... . Treat seizures with diazepam (Valium) or lorazepam (Ativan) ... . Use proparacaine hydrochloride to assist eye irrigation ... . /Poisons A and B/

Embark 2-S Plant Growth Regulator (PBI/Gordon Corporation): Active ingredient: mefluidide, diethanolamine salt 28.0%.|Mefluidide 2-S Concentrate (PBI/Gordon Corporation): Active ingredient: mefluidide, diethanolamine salt 28.0%.|Embark E-Z-TU-Use Plant Growth Regulator (PBI/Gordon Corporation): Active ingredient: mefluidide, diethanolamine salt 3.2%.|EH 1135 PGR (PBI/Gordon Corporation): Active ingredient: mefluidide, diethanolamine salt 21.45%; imazapyr 0.15%; and imazethapyr, ammonium salt 4.09%.

Mefluidide, mefluidide diethanolamine salt, and mefluidide potassium salt are collectively referred to as mefluidide. Mefluidide was first registered in October 1984, mefluidide diethanolamine salt was first registered in March 1973, and mefluidide potassium salt was first registered in December 1988. ... Based on the structural similarities of mefluidide (114001) and its diethanolamine (DEA) (114002) and potassium salts (114003), and the physical and chemical properties of the DEA and potassium salts, EPA has concluded that mefluidide DEA and potassium salts are biologically equivalent to mefluidide and thus they share the same toxicity as free mefluidide.